1. Epidemiology and Global Health
Download icon

Childhood injury after a parental cancer diagnosis

  1. Ruoqing Chen  Is a corresponding author
  2. Amanda Regodón Wallin
  3. Arvid Sjölander
  4. Unnur Valdimarsdóttir
  5. Weimin Ye
  6. Henning Tiemeier
  7. Katja Fall
  8. Catarina Almqvist
  9. Kamila Czene
  10. Fang Fang
  1. Karolinska Institutet, Sweden
  2. Erasmus University, Netherlands
  3. Örebro University, Sweden
Research Article
  • Cited 4
  • Views 1,157
  • Annotations
Cite this article as: eLife 2015;4:e08500 doi: 10.7554/eLife.08500

Abstract

A parental cancer diagnosis is psychologically straining for the whole family. We investigated whether a parental cancer diagnosis is associated with a higher-than-expected risk of injury among children by using a Swedish nationwide register-based cohort study. Compared to children without parental cancer, children with parental cancer had a higher rate of hospital contact for injury during the first year after parental cancer diagnosis (hazard ratio [HR]=1.27, 95% confidence interval [CI]=1.22-1.33), especially when the parent had a comorbid psychiatric disorder after cancer diagnosis (HR=1.41, 95% CI=1.08-1.85). The rate increment declined during the second and third year after parental cancer diagnosis (HR=1.10, 95% CI=1.07-1.14) and became null afterwards (HR=1.01, 95% CI=0.99-1.03). Children with parental cancer also had a higher rate of repeated injuries than the other children (HR=1.13, 95% CI= 1.12-1.15). Given the high rate of injury among children in the general population, our findings may have important public health implications.

Article and author information

Author details

  1. Ruoqing Chen

    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
    For correspondence
    ruoqing.chen@ki.se
    Competing interests
    The authors declare that no competing interests exist.

  2. Amanda Regodón Wallin

    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
    Competing interests
    The authors declare that no competing interests exist.

  3. Arvid Sjölander

    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
    Competing interests
    The authors declare that no competing interests exist.

  4. Unnur Valdimarsdóttir

    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
    Competing interests
    The authors declare that no competing interests exist.

  5. Weimin Ye

    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
    Competing interests
    The authors declare that no competing interests exist.

  6. Henning Tiemeier

    Department of Epidemiology, Erasmus University Medical Center, Erasmus University, Rotterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.

  7. Katja Fall

    Clinical Epidemiology and Biostatistics Unit, School of Health and Medical Sciences, Örebro University Hospital, Örebro University, Örebro, Sweden
    Competing interests
    The authors declare that no competing interests exist.

  8. Catarina Almqvist

    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
    Competing interests
    The authors declare that no competing interests exist.

  9. Kamila Czene

    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
    Competing interests
    The authors declare that no competing interests exist.

  10. Fang Fang

    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
    Competing interests
    The authors declare that no competing interests exist.

Ethics

Human subjects: The study was approved by the Central Ethical Review Board (Centrala etikpr�vningsn�mnden) in Stockholm, Sweden (Reg No. 2013/244-31/4). In accordance with their decision, we did not obtain informed consent from participants involved in the study. All individuals' information was anonymized and de-identified prior to analysis.

Reviewing Editor

  1. Eduardo Franco, McGill University, Canada

Publication history

  1. Received: May 4, 2015
  2. Accepted: October 27, 2015
  3. Accepted Manuscript published: October 31, 2015 (version 1)
  4. Version of Record published: February 9, 2016 (version 2)

Copyright

© 2015, Chen et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,157
    Page views
  • 207
    Downloads
  • 4
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, Scopus, PubMed Central.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Download citations (links to download the citations from this article in formats compatible with various reference manager tools)

Open citations (links to open the citations from this article in various online reference manager services)

Categories and tags

Research organism

Further reading

    1. Epidemiology and Global Health
    2. Evolutionary Biology

    COVID-19 CG enables SARS-CoV-2 mutation and lineage tracking by locations and dates of interest

    Albert Tian Chen et al.
    Research Article

    COVID-19 CG (covidcg.org) is an open resource for tracking SARS-CoV-2 single-nucleotide variations (SNVs), lineages, and clades using the virus genomes on the GISAID database while filtering by location, date, gene, and mutation of interest. COVID-19 CG provides significant time, labor, and cost-saving utility to projects on SARS-CoV-2 transmission, evolution, diagnostics, therapeutics, vaccines, and intervention tracking. Here, we describe case studies in which users can interrogate (1) SNVs in the SARS-CoV-2 spike receptor binding domain (RBD) across different geographical regions to inform the design and testing of therapeutics, (2) SNVs that may impact the sensitivity of commonly used diagnostic primers, and (3) the emergence of a dominant lineage harboring an S477N RBD mutation in Australia in 2020. To accelerate COVID-19 efforts, COVID-19 CG will be upgraded with new features for users to rapidly pinpoint mutations as the virus evolves throughout the pandemic and in response to therapeutic and public health interventions.

    1. Epidemiology and Global Health
    2. Microbiology and Infectious Disease

    Viral load and contact heterogeneity predict SARS-CoV-2 transmission and super-spreading events

    Ashish Goyal et al.
    Research Article

    SARS-CoV-2 is difficult to contain because many transmissions occur during pre-symptomatic infection. Unlike influenza, most SARS-CoV-2 infected people do not transmit while a small percentage infect large numbers of people. We designed mathematical models which link observed viral loads with epidemiologic features of each virus, including distribution of transmissions attributed to each infected person and duration between symptom onset in the transmitter and secondarily infected person. We identify that people infected with SARS-CoV-2 or influenza can be highly contagious for less than one day, congruent with peak viral load. SARS-CoV-2 super-spreader events occur when an infected person is shedding at a very high viral load and has a high number of exposed contacts. The higher predisposition of SARS-CoV-2 towards super-spreading events cannot be attributed to additional weeks of shedding relative to influenza. Rather, a person infected with SARS-CoV-2 exposes more people within equivalent physical contact networks, likely due to aerosolization.

    1. Epidemiology and Global Health
    2. Microbiology and Infectious Disease

    The Spike D614G mutation increases SARS-CoV-2 infection of multiple human cell types

    Zharko Daniloski et al.
    Research Article Updated

    A novel variant of the SARS-CoV-2 virus carrying a point mutation in the Spike protein (D614G) has recently emerged and rapidly surpassed others in prevalence. This mutation is in linkage disequilibrium with an ORF1b protein variant (P314L), making it difficult to discern the functional significance of the Spike D614G mutation from population genetics alone. Here, we perform site-directed mutagenesis on wild-type human-codon-optimized Spike to introduce the D614G variant. Using multiple human cell lines, including human lung epithelial cells, we found that the lentiviral particles pseudotyped with Spike D614G are more effective at transducing cells than ones pseudotyped with wild-type Spike. The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2. Furthermore, trans-complementation of SARS-CoV-2 virus with Spike D614G showed an increased infectivity in human cells. Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants, the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.